1. Borchers, A.T., Stern, J.S., Hackman, R.M., Keen, C.L., Gerschwin, M.E., 1999. Mushrooms, tumors and imunity. Proc Soc Exp Biol Med, 221, 281-293.
  2. Chihara G, “Recent progress in immunopharmacology and therapeutic effects of polysaccharides,” Dev Biol Stand. 1992; 77:191-7.
  3. Czop JK, Valiante NM, Janusz MJ, “Phagocytosis of particulate activators of the human alternative complement pathway through monocyte beta-glucan receptors,” Prog Clin Biol Res. 1989; 297:287-96.
  4. Frey A; Giannasca KT; Weltzin R, t al., “Role of the glycocalyx in regulating access of microparticles to apical plasma membranes of intestinal epithelial cells: implications for microbial attachment and oral vaccine targeting,” J Exp Med, 1996 Sep 1, 184:3, 1045-59.
  5. Ghoneum, M., Wimbley, M., Salem, F., McKlain, A., Attalan, N. and Gill, G. 1995. Immunomodulatory and anticancer effects of active hemicellulose compound (AHCC). International Journal of Immunotherapy 11, 23-28.
  6. Ikekawa, T., Nakanishi, M., Uehara, N., Chihara, G. and Fukuoka, F. 1968. Antitumour action of someBasidiomycetes, especially Phellinus linteus. GANN, 59, 155-157.
  7. Ikekawa, T., Uehara, N., Maeda, Y., Nankinishi, M. and Fukoka, F. 1969. Antitumour activity of aqueousextracts of edible mushrooms. Cancer Research 29, 734-735.
  8. Jaskari,J., Kontula, P., Siitonen, A., Jousimies-Somer, H., Mattila-Sandholm, T., Poutanen, K., 1998. Oat beta-glucan and xylan hydrolysates as selective substrates for Bifidobacterium and Lactobacillus strains. Appl Microbiol Biotechnol, 49, 175-181.
  9. Jason C. Cooper, PharmD, Nannette Turcasso, PharmD., BCPS; “Immunostimulatory Effects of Beta-1, 3-glucan and Acemannan”; Medical University of South Carolina.
  10. Kidd, P.M. 2000. The use of mushroom glucans and proteoglycans in cancer therapy. Alternative Medicine Review 5, 4-27.
  11. Minato, K., Mizuno, M., Ashida, H., Hashimoto, T., Terai, H. and Tsuchida, H. 1999. Influence of storage conditions on immunomodulating activities of Lentinus edodes. International Journal of MedicinalMushrooms 1, 243-250.
  12. Miura NN, Ohno N, Aketagawa J, et al., “Blood clearance of (1-->3)-beta-D-glucan in MRL lpr/lpr mice,” FEMS Immunol Med Microbiol. 1996 Jan; 13(1): 51-57.
  13. Mizuno, T. 1996. A development of antitumour polysaccharides from mushroom fungi. Food Ingredients Journal (Japan), 167, 69-85.
  14. Nicolosi,R., Bell, S.J., Bistrian, B.R., Greenberg, I., Forse, R.A., Blackburn, G.L., 1999. Plasma lipid changes after supplementation withbeta-glucan fiber from yeast. Am J Clin Nutr, 70, 208-212.
  15. Novák M.: beta glukán, historie a současnost. Chemické listy 101, 872-880, 2007.
  16. Patchen ML; D´Alessandro MM; Brook I; Blakely WF; MacVittie TJ, „Glucan:: Mechanisms Involved in Its „Radioprotective“ Effect“, Journal of Leukocyte Biology, Vol 42, Issue 2 95-105
  17. Patchen ML; DiLuzio NR; Jacques P, et al., “Soluble polyglycans enhance recovery from cobalt-60—induced hemopoietic injury,” J Biol Response Mod, 1984 Dec, 3:6, 627-33.
  18. Ross G.D., Větvička V., Yan J., Xia Y., Větvičková J.: Therapeutic intervention with complement and beta glucan in cancer. Immunopharmacology, 42, 1999, 61-74.
  19. Sawai, M., Adachi, Y., Kanai, M., Matsui, S. and Yadomae, T. 2002. “Extraction of conformationally stable (1-6)-branched (1-3)- ?-glucans from premixed edible mushroom powders by cold-alkaline solution”. International Journal of Medicinal Mushrooms (in press).
  20. Teas J, “The dietary intake of Laminarin, a brown seaweed, and breast cancer prevention,” Nutr Cancer. 1983; 4(3): 217-22.
  21. Thornton BP, Větvička V, Pitman M, Goldman RC, Ross GD: “Analysis of the sugar specificity and molecular location of the beta glucan binding lectin site of complement receptor type 3 (CD11b/CD18). J Immunol., 1996, 156: 1235-1246.
  22. Tsukagoshi S, Hashimoto Y, Fujii G, et al., “Krestin (PSK),” Cancer Treat Rev, 1984 Jun, 11:2, 131-55.
  23. Větvička V, Thornton BP, Ross GD: “Soluble beta glucan polysaccharide binding to the lectin site of neutrophil or NK cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells. JClin Invest, 1996, 98:50-61.
  24. Větvička V.: “Beta glucans as immunomodulators”. JANA, Vol. 3, No. 4, 2001.
  25. Wasser SP, Weis AL, “Therapeutic effects of substances occurring in higher Basidiomycetes mushrooms: a modern perspective,” Crit Rev Immunol. 1999; 19(1): 65-96.
  26. Xia Y, Ross GD: CR3. In: Morley BJ, Walport MJ, eds Complement Factbook. Academic Press: London, 1999, 188-197.